Wes Furnback, United States of America

Elysia Group, LLC Health Economics and Outcomes Research

Author Of 1 Presentation

SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF PNEUMOCOCCAL CONJUGATE VACCINES IN EAST AND SOUTHEAST ASIA (ID 241)

Abstract

Background

Pneumococcal conjugate vaccines (PCVs) reduced the incidence of pneumococcal disease. We performed a systematic literature review of the cost-effectiveness of PCVs within East and Southeast Asia.

Methods

We reviewed the MEDLINE and EMBASE databases through 10/11/2019 to identify studies evaluating the cost-effectiveness of PCVs in East and Southeast Asia. Study characteristics, clinical outcomes, cost outcomes, and cost-effectiveness results were extracted, while studies without at least one analysis in East and Southeast Asia were excluded.

Results

We included 32 studies: 3 multi-setting studies and 29 single-setting studies. Within these studies, there were a total of 55 separate analyses comparing pneumococcal vaccination strategies. A PCV (PCV7/10/13) was compared to no vaccination in 45 (81.8%) analyses, and the vaccine was considered cost-effective in 86.7% (39/45) (Table 1). PCV13 and PCV10 were evaluated in 9 (16.4%) analyses. The results comparing PCV10 with PCV13 were heavily dependent on the study funder and modeling assumptions but independent studies found PCV13 cost-effective compared to PCV10 due to broader serotype coverage.

table 1.png

Conclusions

PCVs are generally cost-effective against no vaccination in Asia. This study will support decision-makers in Asia as they consider the clinical and economic value of introducing PCV NIPs and considering higher valent vaccines.

Hide